Life Sciences & Pharma
Redesign how science moves from discovery to patient impact — without weakening evidence, quality or regulatory control.
Artificial intelligence is beginning to reshape the full life sciences value chain: scientific research, clinical development, regulatory and medical work, manufacturing, supply, commercial operations and enterprise knowledge.
The opportunity is not to add AI to every scientific or administrative task.
It is to determine where AI can accelerate evidence, reduce operational friction and improve decisions — while keeping scientific judgement, quality standards and regulated accountability firmly under human control.
I help pharmaceutical, biotech, medtech and life sciences organisations identify high-value AI opportunities, redesign workflows around AI and automation, and turn isolated pilots into governed operating capabilities.
AI can improve the speed and quality of work across the path from science to market.
Expand scientific capacity without lowering the bar for evidence.
Make clinical development more connected, responsive and evidence-led.
Accelerate regulated work while preserving traceability and human accountability.
Increase precision across manufacturing, quality and supply.
Help medical and commercial teams work from better evidence and better context.
Life sciences organisations do not create value by producing more documents or more AI outputs.
They create value by moving reliable evidence through a complex system of scientific, clinical, regulatory, manufacturing and commercial decisions.
The most important question is therefore not:
“Where can we use generative AI?”
It is:
“Where does evidence slow down, fragment or get repeatedly reworked — and how should people, AI, data and systems work together instead?”
A well-designed AI workflow should strengthen the chain of evidence, not create a parallel black box.
AI expands the evidence base. Scientists decide what is scientifically meaningful.
AI prepares and connects. Clinical teams remain accountable for study decisions.
AI can accelerate drafting. It cannot own scientific claims or regulatory accountability.
AI organises the evidence. Quality professionals determine the cause and corrective action.
AI transformation in life sciences requires clear boundaries.
Accelerate the work. Preserve scientific rigour and regulated accountability.
Successful AI transformation requires more than deploying copilots or launching isolated pilots.
It requires redesigning workflows, evidence flows and controls.
Map critical scientific, clinical, regulatory, manufacturing and commercial workflows.
Identify where teams spend time searching, reconciling, rewriting, checking, transferring and waiting for information.
Evaluate each opportunity across:
Not every possible use case should be built.
Prioritise opportunities where value is high, evidence can be controlled and accountability is clear.
Define:
Design how AI integrates with the existing technology and data landscape — research platforms, clinical systems, regulatory repositories, QMS, MES, ERP, CRM, document systems, data platforms and APIs.
Delivery happens with internal teams and appropriate technology or validation partners. My role is operating-model design, workflow architecture, prioritisation and transformation leadership.
Measure scientific, operational and business impact alongside quality and risk.
Scale only where the workflow is understood, evidence remains traceable and the control model works in practice.
Faster does not mean less rigorous
Life sciences AI must operate inside a system designed for scientific integrity, product quality, patient safety and regulatory accountability.
Different workflows require different levels of autonomy.
AI searches, summarises, drafts and prepares.
A qualified person reviews the output before it influences regulated or scientific work.
AI proposes an interpretation or action together with the evidence and sources supporting it.
A qualified person accepts, adjusts or rejects the recommendation.
Automation executes low-risk, repeatable actions inside defined and monitored controls.
Exceptions, low confidence and regulated decisions escalate to qualified people.
AI systems used in regulated environments should be designed around:
AI should accelerate evidence — never weaken the standards used to trust it.
AI Opportunity Assessment
A structured assessment helps distinguish high-impact opportunities from attractive demos.
Critical scientific, clinical, regulated and operational workflows
AI, agent and automation opportunities
By impact, evidence readiness, complexity, regulatory exposure and risk
Initial AI-native workflows and control points
An actionable AI Transformation Roadmap
The result is not a list of AI tools. It is a clear view of where AI can accelerate the path from science to patient impact, what must remain under expert control, and what to do first.
Discuss an AI Opportunity AssessmentAI transformation for Life Sciences in Switzerland
I work at the intersection of executive leadership, finance, operating-model transformation, technology and artificial intelligence.
My approach starts with the scientific and business workflow — not with a specific AI vendor.
I combine strategic and financial discipline shaped by executive leadership experience with hands-on transformation thinking across regulated and operational environments.
I start with how the organisation should operate, not with the tool it should buy.
Pharma · Biotech · MedTech · CROs · CDMOs / CMOs · Life Sciences Services
